Schedule A Meeting

Tax Services for Healthcare and Life Sciences Companies

Medical practices, biotech firms, clinical-stage drug developers, and medical device companies face a tax environment that general CPAs rarely handle well. From Orphan Drug credits to practice entity structuring and multi-state payroll, the right strategy can protect margins and fund future research.

Schedule A Meeting


100% confidential · No spam

The Data Behind the Savings: What Healthcare Tax Planning Actually Returns

'Healthcare and life sciences companies often overpay because R&D credits on clinical research go unclaimed, Section 174 capitalization is applied on default settings, and medical practice entity structures are left on autopilot for years. For a biotech with $12M in revenue and $7M in qualifying research spend, the difference between standard filing and an optimized tax plan can exceed seven figures. Let us assume $12M in revenue, $7M in qualifying R&D payroll, and 21% federal rate.'
Without Planning
Standard Filing With No R&D Claim

$1,050,000

Full 21% federal rate on taxable income with no research credit offset. Section 174 costs capitalized over 5 years with no strategic treatment. No Orphan Drug credit review. Practice entity taxed as a default C-corp with no accountable plan in place for owner benefits.
With Healthcare Tax Strategy
R&D Credit & Entity Optimized

$420,000

R&D credit of $560K claimed on clinical research payroll. Orphan Drug credit captured where applicable. Section 174 capitalization structured to reduce near-term cash impact. Practice entity restructured with an accountable plan. Total savings: $630,000.
Let’s assume $12M revenue, $7M in qualifying R&D payroll
Metric Standard Filing (No R&D Claim) Healthcare Tax Strategy (Optimized)
Taxable Income $5,000,000 $5,000,000
Federal R&D Credit Applied $0 $560,000
Entity & Deduction Savings $0 $70,000
Federal + State Tax Due $1,050,000 $420,000
Total Annual Tax $1,050,000 $420,000
Total Savings from a Strategic Healthcare Filing
$630,000
Savings = (Income × Ratestd) – (Income × Rateopt – R&D Credit – Entity Adjustment)

Where Practices and Biotech Firms Lose the Most on Taxes

Healthcare is unusually complex from a tax standpoint. It touches federal research credits, state licensing rules, insurance reimbursement economics, and practice entity restrictions that vary by jurisdiction. Four issues show up most often when a practice or biotech firm brings in a specialized advisor for the first time.
⚠ The R&D Credit Gap

Unclaimed Credits on Clinical & Preclinical Work

Preclinical research, clinical trial design, assay development, formulation work, and medical device engineering almost always qualify for the federal R&D credit under IRC §41. Life sciences companies using general CPAs routinely miss six or seven figures in credits because the qualifying activity is never documented correctly in time.
⚠ Section 174 Capitalization Shock

The 2026 Impact on Research Spending

Post-TCJA rules require capitalizing and amortizing research costs over 5 years for domestic work and 15 years for foreign CROs. Biotech firms with heavy outsourced clinical work abroad are hit hardest. Strategic contract review and classification can materially soften the near-term cash tax impact.
⚠ Practice Entity Misstructuring

Hidden Tax Cost of the Wrong Practice Structure

Many states require medical, dental, and optometry practices to operate as a professional corporation or professional LLC. Defaulting to a standard S-corp or C-corp without that structure creates compliance issues, while choosing the wrong tax election inside the right structure often adds unnecessary self-employment tax and leaves QBI deductions unclaimed.
⚠ Orphan Drug & Grant Credit Blind Spots

Overlooked Credits Specific to Life Sciences

The Orphan Drug Credit under IRC §45C can offset up to 25% of qualifying clinical testing costs for rare disease therapies. Many biotech founders also receive SBIR or state grants and never review the tax treatment correctly, creating both missed credits and potential compliance exposure on the grant income itself.

Healthcare Tax Compliance: Complete Requirements Checklist

Practices and life sciences companies that prepare correctly for tax season, funding rounds, or partnership transitions typically address each of these items well in advance. Here is what belongs on the readiness checklist.
Healthcare & Life Sciences Readiness Checklist

5 / 5 Complete

Documented R&D Credit Study
Formal §41 study identifying qualifying research work, clinical trial expenses, wages, supplies, and contract research organization costs, with contemporaneous documentation.
Correct Practice Entity Structure
Medical, dental, or specialty practice operating in the correct state-mandated structure with the right tax election, accountable plan, and owner compensation framework.
Section 174 Research Cost Framework
Research expenses classified between domestic and foreign work, capitalized per the required amortization schedule, and modeled forward for cash tax planning.
Orphan Drug & Grant Review
Rare disease therapies reviewed for Orphan Drug Credit eligibility. SBIR, NIH, and state grant income reviewed for correct federal and state tax treatment.
Multi-State Provider & Payroll Compliance
Clinician or sales force operating across states reviewed for payroll, licensing, and nexus exposure. Telehealth and traveling provider rules addressed where applicable.
Quick Readiness Snapshot
Area Requirement
R&D credit §41 study with contemporaneous documentation
Practice structure PC or PLLC with correct tax election
Section 174 5-year domestic / 15-year foreign amortization
Orphan Drug Credit §45C review for rare disease therapies
Multi-state payroll Nexus and licensing review per state

Review Your Healthcare Tax Position Before the Next Filing Deadline

Practices lose margin every year to avoidable tax mistakes. Biotech firms leave credits worth multiples of their audit fees on the table. A partner-level review before year-end can recover most of what would otherwise be overpaid.
Schedule A Meeting

Expert FAQs

Do you work with both medical practices and life sciences startups?
Yes. We support the full healthcare spectrum, from independent medical, dental, and specialty practices to venture-backed biotech firms, medical device companies, and diagnostic startups. Each has a different tax profile. Practices focus on entity structure, owner compensation, and QBI, while life sciences companies focus on R&D credits, Section 174 planning, and investor readiness.
Clinical trial costs are often the largest source of R&D credit for life sciences companies. Qualifying costs include wages for scientific staff, supplies used in experimentation, and a portion of payments to contract research organizations. We run the §41 study across each project phase, so preclinical, Phase I, Phase II, and Phase III spending is evaluated consistently and documented in a way that supports the claim under IRS review.
Yes. Many practices operate in the wrong entity structure or the right structure with the wrong tax election. We review the state rules that apply to the practice type, model out S-corp versus C-corp treatment, set up an accountable plan for owner benefits, and optimize owner compensation so QBI deductions are captured where available. The work is always coordinated with the practice’s healthcare attorney where state rules require it.
Grant income is generally taxable, but the timing and character depend on the grant terms. We review each award for federal and state treatment, confirm whether matching funds create additional exposure, and coordinate with the finance team so grant-funded research is still captured in the R&D credit base where allowed. The goal is to avoid both double counting and missed deductions
Yes. Buyers and investors in healthcare deals pay particular attention to R&D credit claims, Orphan Drug positions, state payroll exposure, and reimbursement-driven revenue recognition. We prepare data room tax documentation, respond to diligence requests, clean up historic filings where needed, and model tax outcomes under different deal structures so founders and partners go into negotiations without surprises.

Disclaimer: This is not tax advice, and it is recommended to consult a tax professional, as every tax situation is unique.